Major drug maker Pfizer will know by the end of the year whether the vaccine is effective. If successful, it will begin distribution in December.
On Sunday, the chief executive of Pfizer Inc. Albert Bourla said that the pharmaceutical giant will already receive accurate data by the end of October whether the experimental COVID-19 vaccine is successful. If approved, it could be distributed in the US by the end of the year.
Burla noted that there is a “good chance” to obtain key data from the last stages of trials within 1.5 months, and now the company is starting to produce a preliminary stock of the drug to make it available at the earliest opportunity.
“We have already started production and have already produced hundreds of thousands of doses, so in case we have good research results, we will be ready,” Burla said.